Atenolol quantification in human plasma by high-performance liquid chromatography: application to bioequivalence study
- PMID: 12866946
- PMCID: PMC2751528
- DOI: 10.1208/ps050221
Atenolol quantification in human plasma by high-performance liquid chromatography: application to bioequivalence study
Abstract
An accurate, precise, and sensitive high-performance liquid chromatography (HPLC) assay was developed for the determination of atenolol in human plasma samples to compare the bioavailability of 2 atenolol tablet (50 mg) formulations in 24 volunteers of both sexes. The study had an open, randomized, 2-period crossover design with a 1-week washout period. Plasma samples were obtained over a 24-hour interval. Atenolol concentrations were analyzed by combined reversed phase liquid chromatography and fluorescence detection (lambda(EX) = 258 nm, lambda(EM) = 300 nm). From the atenolol plasma concentration versus time curves, the following pharmacokinetic parameters were obtained: AUC(0-24h), AUC(0- infinity ), and C(max). The geometric mean of test/reference 50-mg tablets individual percent ratio was 102.2% for AUC(0-24h), and 101.6% for C(max). The 90% confidence intervals (CI) were 100.2% to 105.4% and 100.9% to 103.5%, respectively. Since the 90% CI for both C(max) and AUC(0-24h) were within the 80% to 125% interval proposed by the Food and Drug Administration, it was concluded that atenolol (50-mg tablets) test formulation was bioequivalent to the reference formulation, with regard to both the rate and extent of absorption.
Similar articles
-
Comparative bioavailability of two atenolol tablet formulations in healthy male volunteers after a single dose administration.Int J Clin Pharmacol Ther. 1997 Aug;35(8):324-8. Int J Clin Pharmacol Ther. 1997. PMID: 9266287 Clinical Trial.
-
Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers.Clin Ther. 2010 Mar;32(3):597-606. doi: 10.1016/j.clinthera.2010.03.017. Clin Ther. 2010. PMID: 20399996 Clinical Trial.
-
Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers.Clin Ther. 2009 Apr;31(4):777-83. doi: 10.1016/j.clinthera.2009.04.013. Clin Ther. 2009. PMID: 19446150 Clinical Trial.
-
Amlodipine bioequivalence study: quantification by liquid chromatography coupled to tandem mass spectrometry.Biopharm Drug Dispos. 2001 Dec;22(9):383-90. doi: 10.1002/bdd.282. Biopharm Drug Dispos. 2001. PMID: 11870677 Clinical Trial.
-
HPLC determination of amoxicillin comparative bioavailability in healthy volunteers after a single dose administration.J Pharm Pharm Sci. 2003 May-Aug;6(2):223-30. J Pharm Pharm Sci. 2003. PMID: 12935434 Clinical Trial.
Cited by
-
Supramolecular Interaction of Atenolol and Propranolol with β-Cyclodextrin Spectroscopic Characterization and Analytical Application.Molecules. 2024 Jun 17;29(12):2875. doi: 10.3390/molecules29122875. Molecules. 2024. PMID: 38930938 Free PMC article.
-
Transient outward K+ current reduction prolongs action potentials and promotes afterdepolarisations: a dynamic-clamp study in human and rabbit cardiac atrial myocytes.J Physiol. 2012 Sep 1;590(17):4289-305. doi: 10.1113/jphysiol.2012.235986. Epub 2012 Jun 25. J Physiol. 2012. PMID: 22733660 Free PMC article.
References
-
- Physicians Desk Reference-PDR, 51st ed, Montvale, NJ: Medical Economics Company, Inc; 1999:1548.
-
- Cruickshank JM, McAinsh J. Atenolol and ischemic heart disease: an overview. Curr Med Res Opin. 1991;12:485–496. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical